Roche-Genentech Deal History & Licensing Activity
Roche-Genentech is a life sciences. Over the past three years, Roche-Genentech has been involved in 5 licensing and acquisition transactions, with a primary focus on Other (3 deals). The company currently has 20 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
2
Active Trials
20
Top Modality
Other
Focus Area
Hematological Malignancies
Roche-Genentech Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Roche-Genentech in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| XmAb24306 (IL-15 cytokine therapeutics) | Genentech | Antibodies | Unknown | co development | Jun 25, 2026 |
| XmAb24306 | Genentech | Other | Unknown | co development | Jun 24, 2026 |
Roche-Genentech Pipeline Focus
Therapeutic areas and modalities where Roche-Genentech is most active based on deal history and clinical trial data.
Therapeutic Areas
Roche-Genentech Clinical Pipeline
Roche-Genentech has 20 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
2
Unknown
7
Phase 1
3
Phase 2
6
Phase 3
See How Your Asset Matches Roche-Genentech's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Roche-Genentech Licensing & Deal Activity
Roche-Genentech is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Roche-Genentech ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche-Genentech include Hematological Malignancies (9 deals and trials), Solid Tumors (4 deals and trials), Option Deals (3 deals and trials), and Codev Deals (3 deals and trials). In terms of modality, Roche-Genentech has shown particular interest in other, antibodies, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche-Genentech and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Roche-Genentech's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.